神经母细胞瘤的诊疗一体化:让分子放疗发挥更好效果
神经母细胞瘤生存率仍落后于许多其他儿童恶性肿瘤,亟需新治疗并优化现有治疗。儿童癌症研究基金会组织英国、美国及欧洲大陆的科学家召开研讨会,讨论分子影像与放疗经验,提出开发靶向生长抑素受体和双唾液酸神经节苷脂的载体、α粒子和俄歇电子发射体、联合外照射放疗/免疫治疗/DNA损伤修复抑制剂等方向。
要点
- 神经母细胞瘤表达去甲肾上腺素转运体等多个分子靶点,[123I]MIBG显像和[131I]MIBG治疗已临床应用40年但尚未优化。
- 生长抑素受体和双唾液酸神经节苷脂是替代靶点,但其应用仍处于实验阶段。
- 研讨会提出开发α粒子和俄歇电子发射体、联合外照射放疗/免疫治疗/DNA损伤修复抑制剂等改进方向。
核心结论
- 研讨会旨在促进开发与评估更有效的神经母细胞瘤分子影像和放疗方案。
研究设计与样本
- 慈善机构儿童癌症研究基金会组织研讨会,汇集英国、美国及欧洲大陆的放射化学家、放射生物学家、辐射物理学家、临床研究者(含儿科肿瘤医生和核医学医生)及患者倡导者。
主要发现
- 尽管神经母细胞瘤治疗已有改善,其生存数据仍落后于许多其他儿童恶性肿瘤。
- [123I]MIBG显像和[131I]MIBG治疗靶向去甲肾上腺素转运体这一生理通路,已在临床实践中应用40年,治疗结局良好但[131I]MIBG的使用尚未优化。
- 生长抑素受体和双唾液酸神经节苷脂是替代靶点,但其应用仍处于实验阶段。
- 研讨会讨论了开发靶向生长抑素受体和双唾液酸神经节苷脂的替代载体、具有不同辐射特征的α粒子和俄歇电子发射体等同位素,以及与体外照射放疗、免疫治疗和DNA损伤修复抑制剂的联合。
关键数值与推荐
- 研讨会讨论的进展障碍包括放射性同位素供应不可预测、新型放射性药物的生产、缺乏关于最佳联合治疗方案的数据以及临床设施不足。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New treatments, and better use of existing treatments, are essential to reduce mortality. Neuroblastoma expresses several molecular targets for radionuclide imaging and therapy, of which the most widely exploited is the norepinephrine transporter. [123I]metaiodobenzylguanidine (MIBG) imaging and [131I]MIBG treatment, which target this physiologic pathway, have been in clinical practice for 40 y. Although therapy outcomes have been favorable, [131I]MIBG use has not yet been optimized. Somatostatin receptors and the disialoganglioside are alternative targets, but their use remains experimental. The charity Children's Cancer Research Fund organized a workshop bringing together a broad range of scientists including radiochemists, radiobiologists, radiation physicists, clinical researchers including pediatric oncologists and nuclear medicine physicians, and patient advocates from the United Kingdom, United States, and continental Europe to share their experiences with molecular imaging and radiotherapy of neuroblastoma and discuss potential ways of improving treatment outcomes and access. These include development of alternative vectors targeting somatostatin receptors and disialoganglioside, isotopes such as α-particle and Auger electron emitters with different radiation characteristics, and combinations with external-beam radiotherapy, immunotherapy, and DNA damage repair inhibitors. Barriers to progress discussed included the unpredictable radioisotope supply, production of novel radiopharmaceuticals, lack of data regarding which are the best combination therapies, and insufficient clinical facilities. The aim was to stimulate the development and assessment of more effective treatments.
引用
- Gawne PJ, Bryant HE, DuBois SG, et al. Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better. J Nucl Med. 2025. PMID: 39978816. doi:10.2967/jnumed.124.269121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。